Abstracts tagged "Adalimumab and spondylarthritis"

Abstract Number: 1560 • ACR/ARHP Annual Meeting 2017
Predictors of Long-Term Modified Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated with Adalimumab
Laura C Coates¹, Sonya Abraham², William Tillett³, Philip J Mease⁴, Sofia Ramiro⁵, Tianshuang Wu⁶, Xin Wang⁶, Aileen L. Pangan⁶ and In-Ho Song⁶, ¹University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ²NIHR/Wellcome CRF, Imperial College Healthcare NHS Trust, London, United Kingdom, ³Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose : There is a lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA). Therefore, a modified version of the minimal disease activity (mMDA)1…
Abstract Number: 1545 • ACR/ARHP Annual Meeting 2014
Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab
Philip J. Mease¹, Filip van Den Bosch², Joachim Sieper³, Aileen L. Pangan⁴, Nupun A. Varothai⁴ and In-Ho Song⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Ghent University Hospital, Ghent, Belgium, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Peripheral spondyloarthritis (pSpA) is characterized by arthritis, enthesitis, and/or dactylitis. Enthesitis is considered a core outcome domain for SpA; however, there is no clear…
Abstract Number: 2439 • ACR/ARHP Annual Meeting 2013
Smoking Was Not Associated With Response To Adalimumab Therapy In Patients With Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Denis Poddubnyy², Aileen L. Pangan³, Suchitrita S. Rathmann³ and Jaclyn K. Anderson³, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Cigarette smoking has been reported as a risk factor for early disease onset, higher disease activity, and poor function in patients (pts) with axial…
Abstract Number: 1801 • ACR/ARHP Annual Meeting 2013
Relationship Between MRI and Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Therapy
Désiréé van der Heijde¹, Walter P. Maksymowych², Joachim Sieper³, Robert Lambert⁴, Matthew A. Brown⁵, Suchitrita S. Rathmann⁶, Jaclyn K. Anderson⁶ and Aileen L. Pangan⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Radiology, University of Alberta Hospital, Edmonton, AB, Canada, ⁵Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…
Abstract Number: 1540 • ACR/ARHP Annual Meeting 2013
Sustained Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Treatment
Joachim Sieper¹, Dominique L. Baeten², Filip Van den Bosch³, Suchitrita S. Rathmann⁴, Jaclyn K. Anderson⁴ and Aileen L. Pangan⁴, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Ghent University Hospital, Ghent, Belgium, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…